Susceptibility of multiple myeloma to B-cell lymphoma 2 family inhibitors.

Abstract

Multiple myeloma (MM) is a biologically complex hematological disorder defined by the clonal proliferation of malignant plasma cells producing excessive monoclonal immunoglobulin that interacts with components of the bone marrow microenvironment, resulting in the major clinical features of MM. Despite the development of numerous protocols to treat MM patients, this cancer remains currently incurable; due in part to the emergence of resistant clones, highlighting the unmet need for innovative therapeutic approaches. Accumulating evidence suggests that the survival of MM molecular subgroups depends on the expression profiles of specific subsets of anti-apoptotic B-cell lymphoma (BCL)-2 family members. This review summarizes the mechanisms underlying the anti-myeloma activities of the potent BCL-2 family protein inhibitors, individually or in combination with conventional therapeutic options, and provides an overview of the strong rationale to clinically investigate such interventions for MM therapy.

• Authors: Manon Lernoux, Michael Schnekenburger, Mario Dicato, Marc Diederich
• Journal: Biochemical pharmacology (Biochem Pharmacol) Vol. 188 Pg. 114526 (06 2021) ISSN: 1873-2968 [Electronic] England
• PMID: 33741332 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't, Review)
• Copyright: Copyright © 2021 Elsevier Inc. All rights reserved.

Chemical References

• Proto-Oncogene Proteins c-bcl-2

Topics

• Animals
• Antineoplastic Combined Chemotherapy Protocols (administration & dosage)
• Drug Resistance, Neoplasm (drug effects, physiology)
• Humans
• Immunotherapy (methods)
• Lymphoma, B-Cell (drug therapy, immunology, metabolism)
• Multiple Myeloma (drug therapy, immunology, metabolism)
• Proto-Oncogene Proteins c-bcl-2 (antagonists & inhibitors, immunology, metabolism)
• Tumor Microenvironment (drug effects, physiology)